 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: PARP inhibitor Veliparib combined with optimized FOLFIRI as a second-line treatment for metastatic pancreatic cancer

Clin Cancer Res: PARP inhibitor Veliparib combined with optimized FOLFIRI as a second-line treatment for metastatic pancreatic cancer

 Last Update: 2021-12-24
 Source: Internet
 Author: User

Tags

stage 3 colon cancer

mold 1 control

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

PARP inhibitors and topoisomerase inhibitors have a synergistic effect.

The study is a randomized phase II trial designed to evaluate the efficacy and safety of mFOLFIRI combined with Veliparib vs FOLFIRI (control: irinotecan, fluorouracil, leucovorin) as a second-line treatment for metastatic pancreatic cancer

Recruitment of metastatic pancreatic cancer from September 1, 2016 to December 13, 2017

Overall survival of the two treatment groups

It was planned to recruit 143 patients.

The median overall survival (OS) of the Veliparib group and the control group was 5.

The median progression-free survival of the two treatment groups

Grade 3/4 toxicity was more common in the Veliparib group (69% vs 58%, p=0.

In the FOLFIRI treatment group, the median PFS and OS of HR-DDR-deficient cancers were longer than that of wild-type cancers (PFS: 7.

Overall survival of HR-DDR deficient and wild-type patients treated with FOLFIRI

In summary, Veliparib combined with mFOLFIRI cannot improve the survival rate of patients with metastatic pancreatic cancer

Veliparib combined with mFOLFIRI did not increase the survival rate of patients with metastatic pancreatic cancer.

Original source:

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

N-Desmethyl Imatinib 99%

CAS No.: 404844-02-6

Pharma Grade

$1/MT FOB

Topotecan HCl CAS 119413-54-6 for Scientific Research Chemical Reagents Use only topetecan hydrochloride

CAS No.: 119413-54-6

Pharmacy Grade

$4-5/G FOB

Regorafenib 98% white powder 755037-03-7 Regorafenib (BAY 73-4506)

CAS No.: 755037-03-7

Pharmacy Grade

$4-5/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.